A Case Report of a Patient With Recalcitrant Pemphigus Vulgaris Treated With Rituximab
Mahlatse Cordelia Kgokolo, Lesedi Makgwethele Nevondo, Michaela Beetge, Razia A G Khammissa · 2026
Read A Case Report of a Patient With Recalcitrant Pemphigus Vulgaris Treated With Rituximab by Mahlatse Cordelia Kgokolo, Lesedi Makgwethele Nevondo, Michaela Beetge, Razia A G Khammissa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13428023.txt.
Description
Kgokolo and colleagues reported in 2026 a patient with pemphigus vulgaris, a blistering disease where the immune system attacks the glue between skin cells, whose mouth sores refused standard care. Skin lesions and mouth lesions do not always answer treatment alike. In this case, high-dose steroids cleared the skin, but the mouth disease stayed stubborn.
The turning point was rituximab, an antibody drug that wipes out B cells, the white cells that make the harmful antibodies. After rituximab, the mouth disease finally entered remission. The authors set the case against trial evidence in which most rituximab patients reached full remission off treatment, far more than on steroids alone. They stress tailoring therapy by site, and note a second gain: rituximab spares patients long steroid exposure and its damage to bones, metabolism, and mood.
Catalog record
| CREATOR | Mahlatse Cordelia Kgokolo, Lesedi Makgwethele Nevondo, Michaela Beetge, Razia A G Khammissa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |